• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21936 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2011     Institut national d'excellence en sante et en services sociaux (INESSS) [Rare disease management: experiences from abroad]
2005     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rapid-acting insulin analogues in the treatment of diabetes mellitus type 2]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rapid-acting insulin analogues in the treatment of diabetes mellitus type 1]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rapid-acting insulin analogues in children and adolescents with diabetes mellitus type 1 - follow-up commission]
2012     Andalusian Health Technology Assessment Area (AETSA) [Rapid tests for methicillin resistant Staphylococcus aureus. Carrier screening. Executive summary]
2010     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Rapid systematic review on radiotherapy in lung cancer]
2014     Andalusian Health Technology Assessment Area (AETSA) [Rapid review. Gender dysphoria. Diagnosis, treatment and health outcomes]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid review: alternatives to timolol for the treatment of glaucoma]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: mitigation strategies to counter the shortage of sublingual nitroglycerin sprays and tablets]
2017     Andalusian Health Technology Assessment Area (AETSA) [Rapid response: Effectiveness and safety of hyperthermia in combination with radiation therapy and/or chemotherapy in the treatment of breast, cervix and rectum cancer]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: Cervical cancer: transition from from Pap test screening to HPV testing]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Rapid on-site evaluations of cytological punctures]
2008     Committee for New Health Technology Assessment (CNHTA) [Rapid isoniazid and rifampicin resistance test(sequencing)]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of the artery protection system Embol-X]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of rituximabe in treating B-cell non-hodgkin's lymphoma, low-grade CD 20]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of rituximab for rheumatoid arthritis]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of radiofrequency ablation in the surgical treatment of atrial fibrillation]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of malignant melanoma]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of malignant lymphoma]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of head and neck cancers]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of esophageal cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of colon and rectal cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of breast cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of polyglycolic polymerized matrix artery graft]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of paliperidone for treating schizophrenia]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of natriuretic peptides for diagnosing cardiac insufficiency in patients with acute dyspnea]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of lithium dilution systems for monitoring cardiac output: comparison with available alternatives]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of infliximab for treatment of psoriasis]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of everolimus to prevent renal transplant rejection]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of capecitabine for metastatic breast cancer]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of capecitabine for Dukes'C colorectal cancer (stage III)]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Bortezomib in treating refractory multiple myeloma]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of basal action recombinant insulin, analogous to human insulin, (glargine and determir) for treating type 1 diabetes mellitus]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Alteplase (rt-PA) in the cerebral vascular ischemic accident]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of alpha thyrotropin for diagnosis and treatment of thyroid cancer]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of a disposable multi-dose injection pen pre-filled with human growth hormone (somatropin) solution for injection (Norditropin Nordilet)]
2008     Belgian Health Care Knowledge Centre (KCE) [Rapid assessment of a selection of new treatments for prostate cancer and benign prostate hypertrophy]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Ranibizumab, bevacizumab and aflibercept for age-related macular degeneration]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [Randomized trial on the effects of a psychogeriatric diagnostic day hospital]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Randomized trial of timing of delivery in early preterm fetal growth restriction based on early and late fetal Doppler venous changes versus cardiotocography. Acronym TRUFFLE = Trial of Umbilical and Fetal Flow in Europe]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Ramucirumab for advanced gastric or gastroesophageal junction cancer]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (NSCLC, combination with erlotinib) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (hepatocellular carcinoma) - Addendum to Commission A19-73]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (colorectal cancer) - Addendum to Commission A16-10]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab - benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Raltegravir for the treatment of human immunodeficiency virus infection]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Radium-223-dichloride - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Radium-223 dichloride (mCRPC) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2012     Andalusian Health Technology Assessment Area (AETSA) [Radiosurgery and stereotactic body radiation therapy. Efficacy, safety and efficiency in primary lung cancer and pulmonary oligometastases]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radionuclide therapy - 90Yttrium and 177Lutetium somatostatin analogues for the treatment of inoperable neuroendocrine tumors]
2000     Finnish Office for Health Care Technology Assessment (Finohta) [Radiology in Central Finland - a regional operational model for the 2000s]
2009     Committee for New Health Technology Assessment (CNHTA) [Radiofrequency(RF) ablation of high grade dysplastic nodule of the liver]
2009     Committee for New Health Technology Assessment (CNHTA) [Radiofrequency(RF) ablation of hepatocellular adenoma]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency-assisted surgery in inferior turbinate hypertrophy]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Radiofrequency tonsil reduction]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency percutaneous nucleoplasty in disc disorders]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Radiofrequency denervation for chronic lumbar or cervical spine pain]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Radiofrequency catheter ablation using in-silico modelling in atrial fibrillation]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of tumours of the lung and mediastinal lymph nodes]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of tumors of the urogenital tract (renal cell carcinoma, prostate cancer, uterine leiomyoma)]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of primary tumors of the gastrointestinal tract (colorectal and pancreatic cancer)]
2007     Andalusian Health Technology Assessment Area (AETSA) [Radiofrequency ablation of breast tumours]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of bone tumors (osteoid-osteoma and osseus metastases]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency ablation in benign bone tumors]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Radiofrequency ablation for treatment of symptomatic uterine myomas]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation for the treatment of head and neck cancer]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation for the treatment of breast cancer]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation for the treatment of benign and malign nodules of endocrine organs (thyroid gland and adrenal gland]
2020     Canary Health Service [Radiofrequency ablation for metastatic spinal lesions]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation for hepatocellular carcinoma and colorectal liver metastases]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Radiofrequency ablation for Barrett´s esophagus with high-grade dysplasia or intramucosal cancer: a systematic review]
2009     Committee for New Health Technology Assessment (CNHTA) [Radiofrequency (RF) ablation of primary and secondary lung malignancy]
2010     Committee for New Health Technology Assessment (CNHTA) [Radioembolization]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Radical-7™ – non-invasive continuous monitoring of hemoglobin]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Radiation exposure by medical X-ray applications]
2006     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [R-COD Browser - Web-based software to determine the mortality in Germany from all causes of death according to ICD-10 within the period 1998-2003]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Quantitative electroencephalography]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Quantifying COPD patients preferences for early assisted discharge and inpatient hospital care for COPD exacerbations: a discrete choice experiment]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quality of sleep: Can taking melatonin as a dietary supplement, e.g. in the form of tablets, sprays or soft gums, help to improve sleep?]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Quality of mammographic screening programmes]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Quality of life of stroke patients and their caregivers. Prognosis and results of rehabilitating treatment]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Quality of life in patients operated of total knee or hip artroplasty in Catalonia]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quality of haematological and oncological care in children]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Quality of care in oncology and its measurement ]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Quality indicators for primary care professionals and managers]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Quality control in intensity modulated radiotherapy]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Pyridostigmine with aminopyridines in myasthenia gravis or Lambert-Eaton myasthenic syndrome]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pulsed electromagnetic fields for bone healing disorders]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pulsed electromagnetic fields for bone healing disorders - Addendum to Commission E17-08]
2008     Committee for New Health Technology Assessment (CNHTA) [Pulsed dye laser surgery with flexible fiberlaryngoscope]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pulmonary thrombectomy using a disc retriever for pulmonary artery embolism]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Pulmonary rehabilitation in people with chronic obstructive pulmonary disease (a briefing note)]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Public policies for the coverage of continuous positive airway pressure devices for the treatment of obstructive sleep apnea]
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Psychotherapy - concepts, effect factors and a comparison of legal regulations in three German speaking countries]
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Psychological treatments and psychosocial interventions in forensic psychiatry – a systematic review]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Psychological treatment of personality disorders: a multi-centered randomised controlled trial on the (cost-)effectiveness of schema-focused therapy]